Clinerion, ACRES Partner on Patient Recruitment and Risk-Based Quality Management
eClinical technology services provider Clinerion and the Alliance for Clinical Research Excellence and Safety (ACRES) announced their partnership for accelerating patient recruitment and promoting risk-based quality management.
eClinical technology services provider Clinerion and the Alliance for Clinical Research Excellence and Safety (ACRES) announced their partnership for accelerating patient recruitment and promoting risk-based quality management. The partnership joins ACRES study and site information with Clinerion's Quality Risk Radar solution to significantly extend support of risk-informed decision making during the clinical planning and execution process. Clinerion also will provide ACRES with real-time access to millions of electronic health records (EHRs) coupled with the use of its Patient Recruitment System to find on average 30 times more trial candidates than conventional screening. Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
